Replimune Reports Q2 2026 Financial Results and Commencement of TUDRIQEV Commercial Shipments
Replimune (REPL) reported its fiscal second quarter results, highlighting the transition to a commercial-stage company following the first shipments of its therapy, TUDRIQEV, on October 6, 2026. While product revenue remained at zero for the quarter, early adoption metrics are positive; approximately 20 institutions have added the drug to their formularies and over 15 institutions have already written prescriptions. The company reported a net loss of $57.1 million, an improvement from the $83.1 million loss recorded in the prior year's corresponding quarter. This reduction in loss was driven by lower research and development expenses ($34.4 million) and decreased selling, general, and administrative costs ($21.9 million). Replimune maintains a strong liquidity position with $307.8 million in cash and cash equivalents, providing a runway of over 12 months.
Tickers: $REPL
Topics: cash flow earnings report net loss product launch revenue guidance